Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Humira Clears FDA As First Self-Administered Biologic For Crohn’s Disease

This article was originally published in The Pink Sheet Daily

Executive Summary

Abbott’s adalimumab will compete with Johnson & Johnson’s Remicade in the Crohn’s market following approval of an sBLA for the indication.

You may also be interested in...



UCB’s Cimzia Rejected For Crohn’s By EMEA Committee

Group also refused to recommend Biogen/Elan’s Tysabri for the disease on appeal.

UCB’s Cimzia Rejected For Crohn’s By EMEA Committee

Group also refused to recommend Biogen/Elan’s Tysabri for the disease on appeal.

Humira Drives Abbott’s Second Quarter Performance

With new Crohn’s indication, Humira sales jump 50 percent as firm’s pharma sales grow 17 percent.

Related Content

Topics

UsernamePublicRestriction

Register

PS065687

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel